Drug Discontinuation
HPS Pharmacies wish to advise that Fresenius Kabi have announced the discontinuation of Fresofol® LCT formulations globally. Fresofol® MCT/LCT formulations will remain available.
A summary of the differences between the two formulations is shown below.
| Fresofol® LCT | Fresofol® MCT/LCT | |
|---|---|---|
| Active ingredient | Propofol | Propofol |
| Strength | 1% | 1% |
| Presentation | 20ml ampoule
50ml vial 100ml vial |
20ml ampoule
50ml vial 100ml vial |
| Lipid base | Long-chain triglycerides | Medium chain triglycerides + long-chain triglycerides |
| Antimicrobial preservatives | Nil | Nil |
| Approved indications: | ||
| Induction of general anaesthesia | Adults
Children >3 years |
Adults
Children >1 month |
| Maintenance of general anaesthesia | Adults
Children >3 years |
Adults
Children >3 years Children 1 month – 3 years (procedures not exceeding 60 minutes, unless alternative agents should be avoided |
| Sedation of ventilated patients receiving intensive care | Adults | Adults |
| Monitored conscious sedation for surgical and diagnostic procedures | Adults | Adults |
Retain this notice in a prominent position, including in other related business units for one month. Report any problems identified with medicines, vaccines or medical devices to the TGA.
Should you require further information regarding this matter, please contact your pharmacist at HPS Pharmacies, or Fresenius Kabi on 1300 361 004.
Subscribe Knowledge Centre Updates
Enter your details to receive Knowledge Centre updates